Compare Twist Bioscience Corp (TWST) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Vanguard High Dividend Yield ETF — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Vanguard High Dividend Yield ETF trades at $163. Which is the better fit depends on your goals.
| TWST | VYM | |
|---|---|---|
Market Cap | $8.42B | — |
Sector | Health | — |
52-Week High | $153.10 | $167.03 |
52-Week Low | $24.16 | $137.47 |
Enterprise Value | $8.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
VYM trades at $163.52, down 0.43% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF's forward P/E ratio of 18.85x provides a valuation advantage over SPY, with financial sector exposure potentially benefiting from rising Treasury yields. Recent analysis highlights strong 16% YTD total return and lower volatility compared to the broader market.
The outlook remains cautiously optimistic given VYM's valuation discount and dividend stability, though technical weakness and yield compression to 2.20-2.22% present near-term headwinds. Key risks include sector concentration in financials and market sensitivity to interest rate changes, while institutional sentiment appears balanced between yield appeal and growth concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
